Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

Aspen Neuroscience leverages stem cell biology and genomics for Parkinson's disease treatment. The self-described leading company aims to provide a personalized cell therapy to safely turn the clock back on Parkinson's disease.

Aspen Neuroscience

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Athersys, Inc.

BlueRock Therapeutics LP is a clinical stage cell therapy company that investigates the potential of cell therapy to replace cells damaged or lost to disease in order to create medicines in a new way. Self-described as striving to transform the treatment of degenerative diseases.

BlueRock Therapeutics LP

Eterna focuses on developing innovative off-the-shelf cellular therapies using iPSC-derived mesenchymal stem cells to target solid tumors. The company claims to enhance T-cell anti-tumor activity while limiting systemic exposure.

Metric
Company Name	Eterna Therapeutics Inc.	Aspen Neuroscience	Athersys, Inc.	BlueRock Therapeutics LP
Symbol	ERNA		ATHX
MSH ID	COM:ETERNATX	COM:ASPENNEUROSCIENCE	COM:ATHERSYS	COM:BLUEROCKTX
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	US	US
Stage
Employee Count	8		24
Website	brooklynitx.com	aspenneuroscience.com	athersys.com	bluerocktx.com
LinkedIn		aspen-neuroscience
Founders

Metric
Market Cap	9.90M	833.20K
Enterprise Value
Monthly Web Traffic	270.57K
Web Traffic Growth	0.55
Valuation
Raised Capital

Metric
Revenue	68K	5.33M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-1.29M	5.33M
EBITDA	-19.55M	-75.59M
Operating Income	-20.67M	-77.01M
Net Income	-21.67M	-68.06M
EPS	-4.08	-5.70
Diluted EPS	-4.08	-5.70
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-5.88	1
Operating Profit Margin	-135.73	-515.58
EBITDA Margin	-287.51	-14.20
Net Profit Margin	-147.65	-461.57
Return on Equity	15.58	1.16
Return on Assets	-0.44	-5.03
Return on Capital Employed	-0.50	1.34

COM:ETERNATX

Eterna

Last Close

0.53

22/11 21:00

Market Cap

9.90M

Beta: -

Volume Today

113.60K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.42	-0.01
P/B Ratio	2.34	-0.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	192.73	77.57
EV Multiple	2.09	0.41

Metric
Days Sales Outstanding	12.71K
Days Payables Outstanding	4.45K
Days Inventory Outstanding
Operating Cycle	2.28K
Cash Conversion Cycle	1.79K
Asset Turnover	0.00	0.01

Metric
Operating Cash Flow	-20.41M	-58.95M
Free Cash Flow	-20.43M	-59.35M
Cash Flow to Debt	-0.38	-1.42
Operating Cash Flow/Sales	-101.81	-325.41
Free Cash Flow Yield	-2.54	-29.66

Metric
Cash & Equivalents	7.58M	9.04M
Accounts Receivable	527K	3.70M
Inventory
Goodwill	2.04M
Debt to Capitalization	2.84	-1.04
Debt to Assets	0.79	2.50
Current Ratio	0.73	0.06
Quick Ratio	1.22	0.03

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	28.90	34.17
R&D to Revenue	130.82	370.12
SG&A to Revenue	252.08	133.99